Aripiprazole Tablet
Product Images NDC 70518-0970

14 FDA label images from Remedyrepack Inc. · Packaging, Regulatory Labels, and Product Appearance

Product Visual Gallery

This gallery contains 14 technical images submitted to the FDA as part of the official labeling for Aripiprazole (NDC 70518-0970). Unlike standard consumer photos, these assets often include clinical data figures, molecular chemical structures, and official manufacturer packaging layouts.

As provided by Remedyrepack Inc., these visuals offer a comprehensive scientific overview of the product's physical and chemical identity, aiding pharmacists and researchers in product verification and study.

FDA Label Image

1 (Aripiprazole Tablets 1)

1 (Aripiprazole Tablets 1)
Chemical structure of Aripiprazole showing its molecular components and bonds as a 2D diagram.*
FDA Label Image

1 (Aripiprazole Tablets 2)

1 (Aripiprazole Tablets 2)
A pharmacokinetic chart titled 'Effect of Other Drugs on Aripiprazole' showing fold changes and 90% confidence intervals for AUC and Cmax values of Aripiprazole when combined with various drugs. The x-axis represents change relative to reference without interacting drug, with values ranging from 0.0 to 3.0. Listed interacting drugs include CYP3A4 inhibitor ketoconazole, CYP2D6 inhibitor quinidine, CYP3A4 inducer carbamazepine, gastric acid blocker famotidine, and others such as valproate, lithium, and lorazepam.*
FDA Label Image

1 (Aripiprazole Tablets 3)

1 (Aripiprazole Tablets 3)
A pharmacokinetic graph titled 'Effect of Other Drugs on Aripiprazole' showing fold changes in dehydro-aripiprazole levels with 90% confidence intervals. The x-axis represents change relative to reference without interacting drug, ranging approximately from 0.0 to 3.0. Drugs listed include CYP3A4 inhibitor ketoconazole, CYP2D6 inhibitor quinidine, CYP3A4 inducer carbamazepine, gastric acid blocker famotidine, and others: valproate, lithium, lorazepam, with AUC and Cmax parameters shown for each.*
FDA Label Image

1 (Aripiprazole Tablets 4)

1 (Aripiprazole Tablets 4)
A chart titled 'Effect of Aripiprazole on Other Drugs' depicting fold change and 90% confidence intervals in pharmacokinetic parameters (AUC, Cmax, INR) of various drugs relative to a reference without interacting drug. The x-axis shows change relative to reference from 0.0 to 3.0, and the y-axis lists drugs including dextromethorphan, warfarin (S- and R- enantiomers), omeprazole, lamotrigine, valproate, lithium, lorazepam, venlafaxine, O-desmethylvenlafaxine, and escitalopram. Points with error bars indicate minor shifts mostly near 1.0 without significant deviation.*
FDA Label Image

1 (Aripiprazole Tablets 5)

1 (Aripiprazole Tablets 5)
A forest plot chart titled 'Aripiprazole Fold Change and 90% CI' showing the pharmacokinetic (PK) parameters AUC and Cmax fold changes relative to reference for various special populations including CYP2D6 poor vs. extensive metabolizers, gender, age groups, hepatic impairment levels, and severe renal impairment. Error bars represent 90% confidence intervals across these categories.*
FDA Label Image

1 (Aripiprazole Tablets 6)

1 (Aripiprazole Tablets 6)
A pharmacokinetic (PK) chart displaying the fold change and 90% confidence interval (CI) of dehydro-aripiprazole levels under different conditions, including CYP2D6 metabolizer status, gender, age groups, hepatic impairment severity, and severe renal impairment. The x-axis shows change relative to reference values, and the y-axis lists specific conditions with measurements for AUC and Cmax.*
FDA Label Image

1 (Aripiprazole Tablets 7)

1 (Aripiprazole Tablets 7)
A Kaplan-Meier curve showing the proportion of subjects with relapse over 182 days from randomization, comparing Aripiprazole (solid blue line) versus placebo (dashed red line). The graph includes numbers of subjects at risk for both groups at multiple time points along the x-axis.*
FDA Label Image

1 (Aripiprazole Tablets 8)

1 (Aripiprazole Tablets 8)
A Kaplan-Meier survival curve chart showing proportion with relapse over time in days from randomization, comparing Aripiprazole (solid line) versus Placebo (dashed line). The graph includes the number of subjects at risk at various time points for both groups.*
FDA Label Image

1 (Aripiprazole Tablets 9)

1 (Aripiprazole Tablets 9)
A Kaplan-Meier survival curve graph showing the proportion of subjects with relapse over time in days from randomization for Aripiprazole versus Placebo groups. The graph includes number of subjects at risk at various time points and compares relapse rates between the two treatments over approximately 364 days.*
FDA Label Image

1 (Aripiprazole Tablets 10)

1 (Aripiprazole Tablets 10)
A line graph illustrating the change in YGTSS total TIC score from baseline over eight weeks of treatment. It compares three groups: Aripiprazole low dose, Aripiprazole high dose, and placebo. The y-axis shows least-squares mean change in score, decreasing over time, with both Aripiprazole groups showing greater reductions than placebo.*
FDA Label Image

Mm1 (Aripiprazole 5mg 70518 0970 00)

Mm1 (Aripiprazole 5mg 70518 0970 00)
Aripiprazole 5 mg tablet label showing packaging details for 30 tablets. The label includes the NDC number 70518-0970-00 and indicates repackaging by RemedyRepack Inc., Indiana, PA. Manufacturer information is Amneal Pharma, Ahmedabad, India. Storage instructions and a QR code are also visible.*
FDA Label Image

Mm2 (Aripiprazole 5mg 70518 0970 01)

Mm2 (Aripiprazole 5mg 70518 0970 01)
Aripiprazole 5 mg tablets, oral dosage form, packaged in a box with a quantity of 30 tablets. The label includes the NDC number 70518-0970-01 and indicates the product is repackaged by RemedyRepack Inc., Indiana, PA. Manufacturer details for Amneal Pharma, Ahmedabad, India, are also present. Storage instructions and a QR code appear on the label.*
FDA Label Image

Mm3 (Aripiprazole 5mg 70518 0970 02)

Mm3 (Aripiprazole 5mg 70518 0970 02)
Aripiprazole 5 mg tablet single dose packaging label showing quantity of 1 tablet. Label displays NDC 70518-0970-02 and states repackaging by RemedyRepack Inc., Indiana, PA. Manufacturer information includes Amneal Pharma, Ahmedabad, India. Storage instructions to keep medication out of children's reach and recommended temperature range are also visible.*
FDA Label Image

Mm4 (Aripiprazole 5mg 70518 0970 03)

Mm4 (Aripiprazole 5mg 70518 0970 03)
Aripiprazole 5 mg tablet bottle label from RemedyRepack Inc. The label states a quantity of 180 tablets with NDC 70518-0970-03. It includes storage instructions, manufacturer information (Amneal Pharma, Ahmedabad, India), and a reminder to consult the insert for usual dosage. The label shows the prescription-only status (RX ONLY).*

* About these descriptions: Image descriptions on this page are generated by automated AI analysis of the product label images from the manufacturer's FDA label submission (SPL). They are provided for reference only and may contain errors or omissions. Always rely on the printed label itself and the official FDA labeling, and consult a pharmacist or healthcare professional with any questions about this product.